Search
Alprenolol
go.drugbank.com/drugs/DB00866ApprovedWithdrawnOne of the adrenergic beta-antagonists used as an antihypertensive, anti-anginal, and anti-arrhythmic agent. … Alprenolol is no longer marketed by AstraZeneca, but may still be available in generic varieties.
Categories: Serotonin Receptor Antagonists, Serotonin 5-HT1 Receptor AntagonistsAnisindione
go.drugbank.com/drugs/DB01125ApprovedII, VII, IX, and X, as well as the anticoagulant proteins C and S, in the liver. … Its anticoagulant action is mediated through the inhibition of the vitamin K-mediated gamma-carboxylation of precursor proteins that are critical in forming the formation of active procoagulation factors
Landiolol
go.drugbank.com/drugs/DB12212ApprovedInvestigationalLandiolol is a rapid-acting beta (β)-1 adrenergic receptor blocker that blocks the positive chronotropic effect of the beta-1 selective agonist norepinephrine. … [L51938] It works to reduce the heart rate, myocardial contractility, and conduction velocity.
Ofatumumab
go.drugbank.com/drugs/DB06650ApprovedInvestigational[L12753] The FDA subsequently approved ofatumumab for the treatment of RMS on August 20, 2020. … [L12612] Ofatumumab works by recognizing antigens that are expressed on the tumour cells in certain cancers; however, the antigen is not tumour-specific and can also be found in normal B-cells.
Zilganersen
go.drugbank.com/drugs/DB18161ApprovedInvestigational[L64096] The FDA approved zilganersen on September 3, 2026 for the treatment of Alexander disease in pediatric and adult patients, making it the first and only disease-modifying treatment for the condition … [L64096] Alexander disease is caused by variants in the *GFAP* gene that lead to overproduction and toxic accumulation of GFAP in astrocytes, and dysfunction in astrocytes can over time damage neurons
Luliconazole
go.drugbank.com/drugs/DB08933ApprovedInvestigationalIt was approved by the FDA (USA) in November 2013 and is marketed under the brand name Luzu. Luliconazole is also approved in Japan. … Luliconazole is a topical antifungal agent that acts by unknown mechanisms but is postulated to involve altering the synthesis of fungi cell membranes.
T-cell surface antigen CD2
go.drugbank.com/bio_entities/BE0000719TargetHumansCD2 interacts with lymphocyte function-associated antigen CD58 (LFA-3) and CD48/BCM1 to mediate adhesion between T-cells and other cell types. CD2 is implicated in the triggering of T-cells, the cytoplasmic domain is implicated in the si...
Synonyms: LFA-3 receptor, Rosette receptorInositol 1,4,5-trisphosphate-gated calcium channel ITPR3
go.drugbank.com/bio_entities/BE0009595TargetHumansInositol 1,4,5-trisphosphate-gated calcium channel that, upon 1D-myo-inositol 1,4,5-trisphosphate binding, transports calcium from the endoplasmic reticulum lumen to cytoplasm, thus releasing the intracellular calcium and therefore parti...
Synonyms: IP3 receptor isoform 3, Type 3 InsP3 receptorDeutetrabenazine
go.drugbank.com/drugs/DB12161ApprovedInvestigationalAs with other agents for the treatment of neurodegenerative diseases, deutetrabenazine is a drug to alleviate the motor symptoms of HD and is not proposed to halt the progression of the disease [T28]. … The presence of deuterium in deutetrabenazine increases the half-lives of the active metabolite and prolongs their pharmacological activity by attenuating CYP2D6 metabolism of the compound [A32046].
Leniolisib
go.drugbank.com/drugs/DB16217ApprovedInvestigational[L45758] APDS is a primary immunodeficiency caused by mutations in genes encoding the PI3Kδ, thereby increasing the activity of PI3Kδ, causing immune dysfunction, and elevating susceptibility to infections … The FDA approved leniolisib on March 24, 2023, making it the first treatment for activated phosphoinositide 3-kinase delta syndrome (APDS).